Case Study of Intrahepatic Combined Immunochemotherapy after Hepatic Resection for Four Patients with Liver Metastases from Colorectal Cancer

Masaaki Oka, Tetsuji Uchiyama, Ryoichi Shimizu, Kazuma Yano, Minekatsu Nishida, Shoichi Hazama, Kouji Shimoda, Michinari Suzuki, Kikuo Harada, Takashi Suzuki

Department of Surgery II, Yamaguchi University School of Medicine

We performed intrahepatic combined immunochemotherapy (ACIT) after hepatic resection for patients with liver metastases from colorectal cancer to prevent recurrence in the liver. ACIT consists of 5 different agents, ie, recombinant interleukin-2 (IL-2), OK-432, adriamycin, cyclophosphamide and famotidine. The survival rate of patients with ACIT (40-month survival rate; 100%) was higher than that of 9 patients without intrahepatic therapy (40-month survival rate; 45%). Natural killer activity was augmented significantly after ACIT. Thus, intrahepatic combined immunochemotherapy after hepatic resection for liver metastases from colorectal cancer may be worth performing in further clinical trial.

Key words
liver metastases from colorectal cancer, hepatic resection, intrahepatic combined immunochemotherapy

Reprint requests
Masaaki Oka Department of Surgery II, Yamaguchi University School of Medicine
1144 Kogushi, Ube, 755 JAPAN

Accepted
December 9, 1992

To read the PDF file you will need Abobe Reader installed on your computer.